Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 199Leukemia, Lymphocytic, Chronic, B-Cell 169Leukemia 165Myelodysplastic Syndromes 162Precursor Cell Lymphoblastic Leukemia-Lymphoma 151Lymphoma, Non-Hodgkin 129Lymphoma 120Multiple Myeloma 112Hodgkin Disease 110Lymphoma, Follicular 97Lymphoma, Mantle-Cell 95Lymphoma, Large B-Cell, Diffuse 87Lymphoma, B-Cell, Marginal Zone 79Myeloproliferative Disorders 77Burkitt Lymphoma 75Congenital Abnormalities 73Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Leukemia, Myelomonocytic, Chronic 66Leukemia, Myeloid, Chronic-Phase 64Leukemia, Myeloid, Accelerated Phase 62Recurrence 57Lymphoma, Large-Cell, Immunoblastic 55Waldenstrom Macroglobulinemia 50Anemia, Refractory, with Excess of Blasts 50Primary Myelofibrosis 48Neoplasms, Plasma Cell 47Blast Crisis 47Hematologic Neoplasms 40Leukemia, Prolymphocytic 37Dendritic Cell Sarcoma, Interdigitating 37

Interventions

Cisplatin 28Pemetrexed 24pembrolizumab 12Nivolumab 10Carboplatin 9atezolizumab 7Gemcitabine 7Cyclophosphamide 7durvalumab 6Drug Therapy 6sodium thiosulfate 5Radiotherapy, Intensity-Modulated 5tremelimumab 4aldesleukin 4Radiotherapy 4Interleukin-2 4sargramostim 3Vinorelbine 3Platinum 3Photochemotherapy 3Ipilimumab 3Doxorubicin 3Dihematoporphyrin Ether 3Chemotherapy, Adjuvant 3Cerebral Decortication 3vatalanib 2regorafenib 2niraparib 2lenvatinib 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Mesothelioma, Malignant × fludarabine phosphate × Clear all
NCT02414945 2023-01-10

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

University Health Network, Toronto

Phase 1/2 Completed
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡